• PTC Therapeutics plans a private offering of USD 500 million Convertible Senior Notes due 2031, with an option for USD 50 million more.
• Net proceeds earmarked to repurchase or repay its 1.5% Convertible Senior Notes due 2026.
• Also targets about USD 50 million of common stock repurchases alongside the offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150700PR_NEWS_USPR_____NY83232) on June 15, 2026, and is solely responsible for the information contained therein.